A Massive Shift Will Lead to Gains in Health Care

Groundbreaking innovations are accelerating in health care. And that's creating massive opportunity within this space... [Stansberry Research Logo] Delivering World-Class Financial Research Since 1999 [DailyWealth] A Massive Shift Will Lead to Gains in Health Care By Dr. David Eifrig, editor, Prosperity Investor --------------------------------------------------------------- Lori Alf was certain she was weeks from death... In the late 2000s, Lori had a stubborn cough... pain in her ribs and back... and difficulty breathing. At first, she thought she had a nasty cold. But after her doctor treated her symptoms, they just wouldn't go away. After further testing and a bone marrow biopsy, doctors discovered the worst. They diagnosed Lori with advanced-stage multiple myeloma. Her doctor and family were horrified. Five-year survival for this disease is slightly better than a coin flip, at only 55%... And it was thought to be only treatable, not curable. But a groundbreaking technology changed everything. It's one example of how tech is upending the health care sector... and creating massive opportunity today. --------------------------------------------------------------- Recommended Links: [Doc Eifrig: 'I'm Staking My ENTIRE Reputation on This']( Dr. David "Doc" Eifrig has successfully navigated every crisis you can imagine in 40 years as a financial pro: the 1987 "Black Monday" crash... the dot-com bust... the great financial crisis... and the COVID-19 panic. But he says THIS coming event will top them all. And he's sharing the most important new work of his life. For a short time only, [get the full story here along with a special gift from Doc](. --------------------------------------------------------------- [Last Chance Before June 1 (Tomorrow)]( The most powerful group on Wall Street has spoken. Now you have just days to move your money before this group triggers a wave of dramatic price shocks. Five individual stocks have been flagged for massive potential gains, while dozens of others have been doomed for extraordinary 50% to 90% losses. To understand the difference – and exactly what's coming to the U.S. stock market this summer – [see this before midnight tonight](. --------------------------------------------------------------- Multiple myeloma hijacks a type of white blood cell called plasma cells. These are responsible for making antibodies that kill germs in our bodies. As the cancerous cells multiply, they build up in bone marrow and produce dysfunctional antibodies that interfere with major organs like the kidneys. Lori and her husband traveled from their home in Florida to a myeloma expert at the Dana-Farber Cancer Institute in Boston. Doctors gave her a chemotherapy cocktail that would smash down the cancer enough to salvage some of her own stem cells. These stem cells could be used for a bone marrow transplant. But Lori's cancer was tough. After nine months, the chemo wasn't working. So her doctors started a second round with more aggressive chemo drugs... And it worked. Doctors completed the stem-cell transplant. But the good news didn't last long. Within weeks, it was apparent the cancer was progressing again. For the next several years, Lori spent her time in and out of the hospital... receiving blood transfusions and other care that only treated her worsening symptoms. There wasn't much more the doctors could do. In 2014, and at only 80 pounds, it looked like Lori was near the end. But a new study at the Perelman School of Medicine at the University of Pennsylvania provided a ray of hope. Researchers were looking for volunteers with advanced forms of myeloma like Lori's. They were testing a cutting-edge therapy called chimeric antigen receptor T-cell therapy, or "CAR T-cell" for short. The therapy removes the patient's own immune cells, genetically reengineers them to attack only cancer, and then infuses them back into the body. Doctors essentially create a drug from living tissue that is tailored directly to each patient. Lori had exhausted nearly every option for treatment when she was enrolled in an early-stage clinical trial. Her bone marrow was 95% clogged with myeloma tumors. What happened next was nothing short of miraculous... Nearly seven years after Lori began her battle, the radiology scans showed no tumor cells. None. Zero. Lori is alive and well today. The underlying treatment she was administered was granted breakthrough status by the U.S. Food and Drug Administration ("FDA") – a regulatory classification aimed to speed up the process of approval for lifesaving treatments. Her treatment is one of the earliest examples of the cancer treatments now known as immunotherapy. This method uses the body's own immune cells to fight cancer. Since Lori's treatment, researchers believe many more kinds of cancer can be treated this way. The scientific community has been building new and better drugs for years. And they're coming at a quicker pace... The chart below shows the number of new drugs approved by the FDA since 2000. The FDA clears about 35 drugs per year on average... But approvals have topped that average every year since 2018. Take a look at the increase over time... This is partly driven by new disease threats, like COVID-19, that have forced innovation. It also stems from a modern-day resurgence of diseases like monkeypox and polio. But the real traction is being driven by new therapies, like the one that led to Lori Alf's miraculous recovery... These are aimed at cancer, heart disease, and rare diseases. Many are called "biologic" drugs, meaning they're created from living material sources – like humans, animals, and other microorganisms. These revolutionary medicines cover a wide range of products from vaccines to blood components to gene therapy. They offer newfound hope for the treatment of diseases with no current cure. They can also be targeted to a specific disease within a specific person. Spotting groundbreaking medical advancements before they receive FDA approval can be an incredibly lucrative investment strategy. And now is the time to start paying attention to this space... Many health care companies are making life-changing drugs and medicines. And you can bet they'll be perfectly positioned to benefit from this astounding growth. Here's to our health, wealth, and a great retirement, Dr. David Eifrig --------------------------------------------------------------- Editor's note: In the past two years alone, the $4 trillion health care industry has made huge strides. According to Doc, we have artificial intelligence to thank for that success... But the progress we've seen is just the tip of the iceberg. AI will drive huge advancements for these companies in the coming years. And if you're looking to make outsized gains in this space, the time to get in is now... [Click here to learn the details](. Further Reading The big names in tech are already invested in the AI boom. But that doesn't mean the upside is over. It's still early days for the AI revolution – and the many buying opportunities it will create... [Read more here](. The AI-chatbot market is filled with competition today. But the "Amazon of China" has stepped up as a noteworthy contender. Here's why this "unsung" stock in the AI trend is worth paying attention to now... [Learn more here](. --------------------------------------------------------------- [Tell us what you think of this content]( [We value our subscribers' feedback. To help us improve your experience, we'd like to ask you a couple brief questions.]( [Click here to rate this e-mail]( You have received this e-mail as part of your subscription to DailyWealth. If you no longer want to receive e-mails from DailyWealth [click here](. Published by Stansberry Research. You're receiving this e-mail at {EMAIL}. Stansberry Research welcomes comments or suggestions at feedback@stansberryresearch.com. This address is for feedback only. For questions about your account or to speak with customer service, call 888-261-2693 (U.S.) or 443-839-0986 (international) Monday-Friday, 9 a.m.-5 p.m. Eastern time. Or e-mail info@stansberryresearch.com. Please note: The law prohibits us from giving personalized financial advice. © 2024 Stansberry Research. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Stansberry Research, 1125 N Charles St, Baltimore, MD 21201 or [stansberryresearch.com](. Any brokers mentioned constitute a partial list of available brokers and is for your information only. Stansberry Research does not recommend or endorse any brokers, dealers, or investment advisors. Stansberry Research forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Stansberry Research (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation. This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.